PL1841316T3 - Białko CCN3 do zastosowania w leczeniu i diagnozowaniu chorób nerek - Google Patents

Białko CCN3 do zastosowania w leczeniu i diagnozowaniu chorób nerek

Info

Publication number
PL1841316T3
PL1841316T3 PL06717966T PL06717966T PL1841316T3 PL 1841316 T3 PL1841316 T3 PL 1841316T3 PL 06717966 T PL06717966 T PL 06717966T PL 06717966 T PL06717966 T PL 06717966T PL 1841316 T3 PL1841316 T3 PL 1841316T3
Authority
PL
Poland
Prior art keywords
ccn3
diseases
protein
treatment
diagnosis
Prior art date
Application number
PL06717966T
Other languages
English (en)
Inventor
Bruce L Riser
Bernard Perbal
Original Assignee
Univ Rosalind Franklin Medicine & Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rosalind Franklin Medicine & Science filed Critical Univ Rosalind Franklin Medicine & Science
Publication of PL1841316T3 publication Critical patent/PL1841316T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL06717966T 2005-01-10 2006-01-10 Białko CCN3 do zastosowania w leczeniu i diagnozowaniu chorób nerek PL1841316T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64272805P 2005-01-10 2005-01-10
PCT/US2006/000833 WO2006074452A2 (en) 2005-01-10 2006-01-10 Regulation of ccn2 by ccn3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases
EP06717966A EP1841316B1 (en) 2005-01-10 2006-01-10 CCN3 protein for use in the treatment and diagnosis of renal diseases

Publications (1)

Publication Number Publication Date
PL1841316T3 true PL1841316T3 (pl) 2011-09-30

Family

ID=36648253

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06717966T PL1841316T3 (pl) 2005-01-10 2006-01-10 Białko CCN3 do zastosowania w leczeniu i diagnozowaniu chorób nerek

Country Status (10)

Country Link
EP (1) EP1841316B1 (pl)
JP (1) JP4834677B2 (pl)
AT (1) ATE506961T1 (pl)
AU (1) AU2006203851B8 (pl)
CA (1) CA2597794A1 (pl)
DE (1) DE602006021534D1 (pl)
DK (1) DK1841316T3 (pl)
ES (1) ES2395260T3 (pl)
PL (1) PL1841316T3 (pl)
WO (1) WO2006074452A2 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0618748D0 (en) * 2006-09-22 2006-11-01 Univ Belfast Peptide
WO2010048347A2 (en) * 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5939584B2 (ja) * 2010-04-02 2016-06-22 ロザリンド フランクリン ユニバーシティー オブ メディスン アンド サイエンス 治療用ｃｃｎ３ペプチドおよびそれらの類似体
US9114112B2 (en) * 2010-04-02 2015-08-25 Rosalind Franklin University Of Medicine And Science CCN3 and CCN3 peptides and analogs thereof for therapeutic uses
WO2011134063A1 (en) * 2010-04-26 2011-11-03 UNIVERSITé LAVAL Ccn3 and uses thereof against metabolic syndrome- associated disorders
US10028906B2 (en) 2016-03-22 2018-07-24 Rosalind Franklin University Of Medicine And Science Method and kit for treating a solid tumor and associated desmoplasia
EP3711772A1 (en) 2019-03-20 2020-09-23 Oslo Universitetssykehus HF Recombinant proteins and fusion proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009940A1 (en) * 2000-10-20 2004-01-15 Coleman Michael E. Gene delivery formulations and methods for treatment of ischemic conditions
FR2825928B1 (fr) * 2001-06-18 2004-04-02 Ecole Norm Superieure Cachan Composition pharmaceutique pour le diagnostic, la prevention ou le traitement d'une pathologie tumorale, comprenant un agent modulateur de l'etat polymerisation de l'actine
EP1382347A1 (en) * 2002-07-17 2004-01-21 UNIVERSITE PARIS 7 - Denis DIDEROT Use of CCN protein family members for the treatment of disorder associated to an altered calcium and/or sodium flux
WO2004090109A2 (en) * 2003-03-31 2004-10-21 Munin Corporation Ccn3 compositions and methods
CA2582224A1 (en) * 2004-09-28 2006-04-06 Lester F. Lau Compositions and methods for modulating tissue regeneration and chemotactic responses

Also Published As

Publication number Publication date
EP1841316A2 (en) 2007-10-10
EP1841316B1 (en) 2011-04-27
EP1841316A4 (en) 2008-07-09
WO2006074452A3 (en) 2006-11-16
AU2006203851B8 (en) 2012-11-15
DE602006021534D1 (de) 2011-06-09
JP4834677B2 (ja) 2011-12-14
CA2597794A1 (en) 2006-07-13
AU2006203851B2 (en) 2012-04-12
WO2006074452A2 (en) 2006-07-13
JP2008526890A (ja) 2008-07-24
ES2395260T3 (es) 2013-02-11
DK1841316T3 (da) 2011-08-08
AU2006203851A1 (en) 2006-07-13
ATE506961T1 (de) 2011-05-15

Similar Documents

Publication Publication Date Title
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
IL177015A0 (en) Improved modalities for the treatment of degenerative diseases of the retina
EA200700886A1 (ru) Соединение тиадиазола и его применение
WO2008122441A3 (en) Anti-amyloid antibodies and their use in diagnosis and therapy of amyloid diseases
MX2009011898A (es) Composiciones y metodos para tratar trastornos asociados con retencion de sal o fluido.
WO2009026657A8 (en) Flavonoid ppar agonists
UA85559C2 (en) Aminobenzophenone compounds
EP2175879A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH PRION PROTEIN
TNSN07191A1 (en) Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
MY145439A (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
EP2018377A4 (en) 2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR CONDITION IN WHICH THE INHIBITION OF HUMAN NEUTROPHILUS ELASTASE HAS A BENEFIT EFFECT
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
WO2007136518A3 (en) Treatment of autoimmune disorders
WO2010059969A8 (en) Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
TNSN08277A1 (en) Materials and methods for treating chronic fibrotic disease
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
PL1841316T3 (pl) Białko CCN3 do zastosowania w leczeniu i diagnozowaniu chorób nerek
GB2488303A (en) CDK5 inhibitors and therapeutic uses thereof
WO2008073466A3 (en) Alpha b-crystallin as a therapy for inflammation
PH12012500296A1 (en) Anti-angiogenesis therapy for the treatment of previously treated breast cancer
EA200801244A1 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
WO2006029142A3 (en) Methods and systems for treating asthma and other respiratory diseases